Interview with the Chairman, President & CEO: Soligenix, Inc. (NASDAQ:SNGX)
Dr. Christopher J. Schaber is presently Chairman, President and CEO of Soligenix, Inc. (NASDAQ:SNGX), a rare disease biotechnology company developing drug therapies for multiple orphan diseases, which includes a Phase III pivotal clinical trial for cutaneous T-cell lymphoma and a Phase III pivotal trial for oral mucositis in head and neck cancer. Dr. Schaber has spent his 28-year career dedicated to the development of drug therapies in rare diseases and areas of unmet medical need. Profile
TWST: Bring us up to speed on the company’s late-stage drug candidates and their development status.
Dr. Schaber: As you may recall, we have two active segments at Soligenix: a